{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:41:33Z","timestamp":1791726093142,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Natural Science Foundation of Fujian Province","award":["2022J01776"],"award-info":[{"award-number":["2022J01776"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-37583-y","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T23:44:25Z","timestamp":1771976665000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cancer-Associated fibroblasts regulate the development of cholangiocarcinoma through IL-6\/STAT3\/AKR1C3 signaling axis"],"prefix":"10.1038","volume":"16","author":[{"given":"Tian-cong","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-du","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-xu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-ya","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-zong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Feng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"37583_CR1","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/s0140-6736(13)61903-0","volume":"383","author":"N Razumilava","year":"2014","unstructured":"Razumilava, N., Gores, G. J. & Cholangiocarcinoma Lancet 383, 2168\u20132179, doi:https:\/\/doi.org\/10.1016\/s0140-6736(13)61903-0 (2014).","journal-title":"Lancet"},{"key":"37583_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.5009\/gnl15568","volume":"11","author":"B Blechacz","year":"2017","unstructured":"Blechacz, B. & Cholangiocarcinoma Current knowledge and new developments. Gut Liver. 11, 13\u201326. https:\/\/doi.org\/10.5009\/gnl15568 (2017).","journal-title":"Gut Liver"},{"key":"37583_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","volume":"7","author":"PJ Brindley","year":"2021","unstructured":"Brindley, P. J. et al. Cholangiocarcinoma. Nat. Rev. Dis. Primers. 7, 65. https:\/\/doi.org\/10.1038\/s41572-021-00300-2 (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"37583_CR4","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jcmgh.2023.01.006","volume":"15","author":"F Ying","year":"2023","unstructured":"Ying, F., Chan, M. S. M. & Lee, T. K. W. Cancer-Associated fibroblasts in hepatocellular carcinoma and cholangiocarcinoma. Cell. Mol. Gastroenterol. Hepatol. 15, 985\u2013999. https:\/\/doi.org\/10.1016\/j.jcmgh.2023.01.006 (2023).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"37583_CR5","doi-asserted-by":"publisher","unstructured":"Montori, M. et al. Cancer-Associated fibroblasts in cholangiocarcinoma: current knowledge and possible implications for therapy. J. Clin. Med. 11 https:\/\/doi.org\/10.3390\/jcm11216498 (2022).","DOI":"10.3390\/jcm11216498"},{"key":"37583_CR6","doi-asserted-by":"publisher","unstructured":"Thongchot, S. et al. Cancer-Associated Fibroblast-Derived IL-6 determines unfavorable prognosis in cholangiocarcinoma by affecting Autophagy-Associated chemoresponse. Cancers (Basel). 13. https:\/\/doi.org\/10.3390\/cancers13092134 (2021).","DOI":"10.3390\/cancers13092134"},{"key":"37583_CR7","doi-asserted-by":"publisher","first-page":"897368","DOI":"10.3389\/fphar.2022.897368","volume":"13","author":"Y Kittirat","year":"2022","unstructured":"Kittirat, Y. et al. Interleukin-6-derived cancer-associated fibroblasts activate STAT3 pathway contributing to gemcitabine resistance in cholangiocarcinoma. Front. Pharmacol. 13, 897368. https:\/\/doi.org\/10.3389\/fphar.2022.897368 (2022).","journal-title":"Front. Pharmacol."},{"key":"37583_CR8","doi-asserted-by":"publisher","first-page":"597672","DOI":"10.3389\/fonc.2020.597672","volume":"10","author":"S Chen","year":"2020","unstructured":"Chen, S. et al. Magnolol suppresses pancreatic cancer development in vivo and in vitro via negatively regulating TGF-\u03b2\/Smad signaling. Front. Oncol. 10, 597672. https:\/\/doi.org\/10.3389\/fonc.2020.597672 (2020).","journal-title":"Front. Oncol."},{"key":"37583_CR9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.mce.2018.07.002","volume":"489","author":"TM Penning","year":"2019","unstructured":"Penning, T. M. AKR1C3 (type 5 17\u03b2-hydroxysteroid dehydrogenase\/prostaglandin F synthase): roles in malignancy and endocrine disorders. Mol. Cell. Endocrinol. 489, 82\u201391. https:\/\/doi.org\/10.1016\/j.mce.2018.07.002 (2019).","journal-title":"Mol. Cell. Endocrinol."},{"key":"37583_CR10","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1097\/cm9.0000000000001379","volume":"134","author":"XZ Xiao","year":"2021","unstructured":"Xiao, X. Z., Lin, L. Y., Zhuang, M. K., Zhong, C. M. & Chen, F. L. Roles of AKR1C3 in malignancy. Chin. Med. J. (Engl). 134, 1052\u20131054. https:\/\/doi.org\/10.1097\/cm9.0000000000001379 (2021).","journal-title":"Chin. Med. J. (Engl)"},{"key":"37583_CR11","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1038\/s41388-022-02379-7","volume":"41","author":"D Pan","year":"2022","unstructured":"Pan, D. et al. AKR1C3 regulated by NRF2\/MAFG complex promotes proliferation via stabilizing PARP1 in hepatocellular carcinoma. Oncogene 41, 3846\u20133858. https:\/\/doi.org\/10.1038\/s41388-022-02379-7 (2022).","journal-title":"Oncogene"},{"key":"37583_CR12","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.18632\/aging.202380","volume":"13","author":"P Zhu","year":"2021","unstructured":"Zhu, P. et al. Diagnostic and prognostic values of AKR1C3 and AKR1D1 in hepatocellular carcinoma. Aging (Albany NY). 13, 4138\u20134156. https:\/\/doi.org\/10.18632\/aging.202380 (2021).","journal-title":"Aging (Albany NY)"},{"key":"37583_CR13","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s13402-020-00571-z","volume":"44","author":"C Peraldo-Neia","year":"2021","unstructured":"Peraldo-Neia, C. et al. AKR1C3 is a biomarker and druggable target for oropharyngeal tumors. Cell. Oncol. (Dordr). 44, 357\u2013372. https:\/\/doi.org\/10.1007\/s13402-020-00571-z (2021).","journal-title":"Cell. Oncol. (Dordr)"},{"key":"37583_CR14","doi-asserted-by":"publisher","first-page":"110038","DOI":"10.1016\/j.cellsig.2021.110038","volume":"84","author":"D Pan","year":"2021","unstructured":"Pan, D. et al. AKR1C3 decreased CML sensitivity to Imatinib in bone marrow microenvironment via dysregulation of miR-379-5p. Cell. Signal. 84, 110038. https:\/\/doi.org\/10.1016\/j.cellsig.2021.110038 (2021).","journal-title":"Cell. Signal."},{"key":"37583_CR15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jsbmb.2013.05.012","volume":"137","author":"AO Adeniji","year":"2013","unstructured":"Adeniji, A. O., Chen, M. & Penning, T. M. AKR1C3 as a target in castrate resistant prostate cancer. J. Steroid Biochem. Mol. Biol. 137, 136\u2013149. https:\/\/doi.org\/10.1016\/j.jsbmb.2013.05.012 (2013).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"37583_CR16","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.7150\/ijms.9239","volume":"11","author":"J Zhao","year":"2014","unstructured":"Zhao, J. et al. AKR1C3 overexpression mediates methotrexate resistance in choriocarcinoma cells. Int. J. Med. Sci. 11, 1089\u20131097. https:\/\/doi.org\/10.7150\/ijms.9239 (2014).","journal-title":"Int. J. Med. Sci."},{"key":"37583_CR17","doi-asserted-by":"publisher","first-page":"823491","DOI":"10.3389\/fonc.2022.823491","volume":"12","author":"J Zheng","year":"2022","unstructured":"Zheng, J., Yang, Z., Li, Y., Yang, L. & Yao, R. Knockdown of AKR1C3 promoted Sorafenib sensitivity through inhibiting the phosphorylation of AKT in hepatocellular carcinoma. Front. Oncol. 12, 823491. https:\/\/doi.org\/10.3389\/fonc.2022.823491 (2022).","journal-title":"Front. Oncol."},{"key":"37583_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3389\/fmed.2020.00113","volume":"7","author":"K Pant","year":"2020","unstructured":"Pant, K., Richard, S., Peixoto, E. & Gradilone, S. A. Role of glucose metabolism reprogramming in the pathogenesis of cholangiocarcinoma. Front. Med. (Lausanne). 7, 113. https:\/\/doi.org\/10.3389\/fmed.2020.00113 (2020).","journal-title":"Front. Med. (Lausanne)"},{"key":"37583_CR19","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jhep.2022.04.038","volume":"77","author":"C Raggi","year":"2022","unstructured":"Raggi, C., Taddei, M. L., Rae, C., Braconi, C. & Marra, F. Metabolic reprogramming in cholangiocarcinoma. J. Hepatol. 77, 849\u2013864. https:\/\/doi.org\/10.1016\/j.jhep.2022.04.038 (2022).","journal-title":"J. Hepatol."},{"key":"37583_CR20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.mce.2008.04.004","volume":"289","author":"S Wang","year":"2008","unstructured":"Wang, S., Yang, Q., Fung, K. M. & Lin, H. K. AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K\/Akt proliferative signaling pathway in human prostate cancer cells. Mol. Cell. Endocrinol. 289, 60\u201366. https:\/\/doi.org\/10.1016\/j.mce.2008.04.004 (2008).","journal-title":"Mol. Cell. Endocrinol."},{"key":"37583_CR21","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1111\/cas.13332","volume":"108","author":"H Kitamura","year":"2017","unstructured":"Kitamura, H. et al. Interleukin-6\/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy. Cancer Sci. 108, 1947\u20131952. https:\/\/doi.org\/10.1111\/cas.13332 (2017).","journal-title":"Cancer Sci."},{"key":"37583_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","volume":"33","author":"T Hirano","year":"2021","unstructured":"Hirano, T. IL-6 in inflammation, autoimmunity and cancer. Int. Immunol. 33, 127\u2013148. https:\/\/doi.org\/10.1093\/intimm\/dxaa078 (2021).","journal-title":"Int. Immunol."},{"key":"37583_CR23","doi-asserted-by":"publisher","first-page":"760971","DOI":"10.3389\/fonc.2021.760971","volume":"11","author":"J Xu","year":"2021","unstructured":"Xu, J., Lin, H., Wu, G., Zhu, M. & Li, M. IL-6\/STAT3 is a promising therapeutic target for hepatocellular carcinoma. Front. Oncol. 11, 760971. https:\/\/doi.org\/10.3389\/fonc.2021.760971 (2021).","journal-title":"Front. Oncol."},{"issue":"Suppl 1","key":"37583_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000167859","volume":"79","author":"H Isomoto","year":"2009","unstructured":"Isomoto, H. Epigenetic alterations in cholangiocarcinoma-sustained IL-6\/STAT3 signaling in cholangio- carcinoma due to SOCS3 epigenetic Silencing. Digestion 79 (Suppl 1), 2\u20138. https:\/\/doi.org\/10.1159\/000167859 (2009).","journal-title":"Digestion"},{"key":"37583_CR25","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41419-019-1506-4","volume":"10","author":"K Leng","year":"2019","unstructured":"Leng, K. et al. Akirin2 is modulated by miR-490-3p and facilitates angiogenesis in cholangiocarcinoma through the IL-6\/STAT3\/VEGFA signaling pathway. Cell. Death Dis. 10, 262. https:\/\/doi.org\/10.1038\/s41419-019-1506-4 (2019).","journal-title":"Cell. Death Dis."},{"key":"37583_CR26","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/hep.26705","volume":"59","author":"T Zheng","year":"2014","unstructured":"Zheng, T. et al. Gankyrin promotes tumor growth and metastasis through activation of IL-6\/STAT3 signaling in human cholangiocarcinoma. Hepatology 59, 935\u2013946. https:\/\/doi.org\/10.1002\/hep.26705 (2014).","journal-title":"Hepatology"},{"key":"37583_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao, X. et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol. Cancer. 20, 131. https:\/\/doi.org\/10.1186\/s12943-021-01428-1 (2021).","journal-title":"Mol. Cancer"},{"key":"37583_CR28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","volume":"18","author":"X Chen","year":"2019","unstructured":"Chen, X. & Song, E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat. Rev. Drug Discov. 18, 99\u2013115. https:\/\/doi.org\/10.1038\/s41573-018-0004-1 (2019).","journal-title":"Nat. Rev. Drug Discov"},{"key":"37583_CR29","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1097\/hep.0000000000000206","volume":"79","author":"P Cantallops Vil\u00e0","year":"2024","unstructured":"Cantallops Vil\u00e0, P., Ravichandra, A., Agirre Lizaso, A., Perugorria, M. J. & Aff\u00f2, S. Heterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma. Hepatology 79, 941\u2013958. https:\/\/doi.org\/10.1097\/hep.0000000000000206 (2024).","journal-title":"Hepatology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37583-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37583-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37583-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T10:28:58Z","timestamp":1774607338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37583-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["37583"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-37583-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"12 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author (s) declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"10467"}}